New developments in the management of hepatitis C virus infection: focus on boceprevir
Marina Berenguer,1–3 F Xavier López-Labrador4–6
1Hepatology-Liver Transplantation Unit, Digestive Medicine Service, Hospital Universitari La Fe, Valencia, Spain; 2Department of Medicine, University of Valencia, Valencia, Spain; 3CIBERehd, Instituto de Salud Carlos III, Madrid, Spain; 4CSISP, Center for Public Health Research, Public Health Department, Generalitat Valenciana, Valencia, Spain; 5Microbiology Department and Institut Cavanilles, University of Valencia, Valencia, Spain; 6CIBEResp, Instituto de Salud Carlos III, Madrid, Spain
Abstract: Chronic hepatitis C virus infection is an important public health problem, and the standard treatment (combination of pegylated interferon-α and ribavirin) has an effectiveness rate of only 40%–50%. Novel virus-specific drugs have recently been designed, and multiple compounds are under development. The approval for the clinical use of direct-acting antivirals in 2011 (boceprevir [BOC] and telaprevir, viral NS3 protease inhibitors) has increased recovery rates by up to 70%. Therefore, a highly effective treatment has been envisioned for the first time. This paper focuses on BOC and the implementation of new BOC-based treatment regimes.
Keywords: HCV, antiviral therapy, protease inhibitors, viral resistance
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]